Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 110, Issue 1, 2000, Pages 154-160

  Wuchter, Christian ^a   Karawajew, Leonid ^a   Ruppert, Velia ^a   Schrappe, Martin ^b   Harbott, Jochen ^c   Ratei, Richard ^a   Dörken, Bernd ^a   Ludwig, Wolf Dieter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bcl 2; CD95; Childhood ALL

Indexed keywords

FAS ANTIGEN; GLYCOPROTEIN P; PREDNISONE; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CYTOGENETICS; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOLOGICAL MARKERS; CHILD; DRUG RESISTANCE, MULTIPLE; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, T-CELL, ACUTE; MALE; P-GLYCOPROTEIN; PREDNISOLONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECURRENCE; REMISSION INDUCTION;

EID: 0033886840     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02147.x     Document Type: Article

References (47)

1. The Bcl-2 protein family: Arbiters of cell survival
2. Anti-inflammatory mechanisms of glucocorticoids
3. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia
4. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
5. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)
6. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
7. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia
8. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase
9. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia
10. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87
11. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program
12. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia
13. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
14. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
15. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: A report on 60 cases
16. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications
17. Apoptosis and the dilemma of cancer chemotherapy
18. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia
19. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase
20. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: Possible correlation with sensitivity to chemotherapy
21. Hyperdiploid acute lymphoblastic leukemia with 51-65 chromosomes: A distinct biological entity with a marked propensity to undergo apoptosis
22. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia
23. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells
24. Inhibition of in vitro spontaneous apoptosis by II-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukaemia
25. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs
26. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis
27. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
28. The proto-oncogene Bcl-2 and its role in regulating apoptosis
29. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate
30. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
31. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia
32. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy
33. ISCN 1995, Guidelines for Cancer Cytogenetics
34. Apoptosis by death factor
35. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation
36. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis
37. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
38. The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia
39. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia
40. Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: The significance of initial therapy response in blood and bone marrow
41. Inhibited apoptosis and drug resistance in acute myeloid leukaemia
42. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis
43. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A Children's Cancer Group Study
44. Expression of the multidrug resistance P-glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: Absence of correlation with response to treatment
45. Clinical significance of CD95, Bcl-2 and Bax expression in adult de novo acute myeloid leukemia in context of P-glycoprotein function maturational stage and cytogenetics
46. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
47. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression